CoChat

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

Open access
Garner, Rachel, Gopalakrishnan, Shobha, McCauley, John A., Bednar, Rodney A., Gaul, Stanley L., Mosser, Scott D., Kiss, Laszlo, Lynch, Joseph J., Patel, Shil, Fandozzi, Christine, Lagrutta, Armando, Briscoe, Richard, Liverton, Nigel J., Paterson, Blake M., Vornov, James J., Mazhari, Reza · 2015 · Pharmacology Research & Perspectives
Cited by 41

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The preclinical pharmacodynamic and pharmacokinetic properties of 4‐methylbenzyl (3S, 4R)‐3‐fluoro‐4‐[(Pyrimidin‐2‐ylamino) methyl] piperidine‐1‐carboxylate (CERC‐301), an orally bioavailable selective N‐methyl‐D‐aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist, were characterized to develop a translational approach based on receptor occupancy (RO) to guide CERC‐301 dose selection in clinical trials of major depressive disorder.CERC‐301 demonstrated high‐binding affinity (Ki, 8.1 nmol L−1) specific to GluN2B with an IC50 of 3.6 nmol L−1 and no off‐target activity.CERC‐301 efficacy was demonstrated in the forced swim test with an efficacy dose (ED50) of 0.3–0.7 mg kg−1(RO, 30–50%); increase in locomotor activity was observed at ED50 of 2 mg kg−1, corresponding to an RO of 75%. The predicted 50%RO concentration (Occ 50) in humans was 400 nmol L−1, similar to that predicted for rat, dog, and monkey (300, 200, and 400 nmol L−1, respectively). Safety pharmacology and neurotoxicity studies raised no specific safety concerns. A first‐in‐human study in healthy males demonstrated a dose‐proportional pharmacokinetic profile, with Tmax of ~1 h and t1/2 of 12–17 h. Based on the preclinical and pharmacodynamic data, doses of ≥8 mg in humans are hypothesized to have an acceptable safety profile and result in clinically relevant peak plasma exposure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/prp2.198

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 41

Metadata

Authors
Garner, R., Gopalakrishnan, S., McCauley, J. A., Bednar, R. A., Gaul, S. L., Mosser, S. D., Kiss, L., Lynch, J. J., Patel, S., Fandozzi, C., Lagrutta, A., Briscoe, R., Liverton, N. J., Paterson, B. M., Vornov, J. J., & Mazhari, R.
Venue
Pharmacology Research & Perspectives
Publisher
Wiley
Published
2015-12
Volume
3
Issue
6
Pages
e00198-e00198
ISSN
2052-1707 (ISSN-L)
OpenAlex
W2341561439
Cited by
41
References
9
FWCI
3.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist. https://app.cochat.ai/papers/10.1002/prp2.198
The paper
Garner, R., Gopalakrishnan, S., McCauley, J. A., Bednar, R. A., Gaul, S. L., Mosser, S. D., Kiss, L., Lynch, J. J., Patel, S., Fandozzi, C., Lagrutta, A., Briscoe, R., Liverton, N. J., Paterson, B. M., Vornov, J. J., & Mazhari, R. (2015). Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.